Tammy Melissa Solomon
Family · Greeneville, TNNPI 1801379078
Payments from drug & device makers
Across 185 payments — averaging $14.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$825
- AbbVie$592
- Lilly USA, LLC$332
- Otsuka America Pharmaceutical, Inc.$104
- Mylan Specialty L.p.$100
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$81
- plus $646 from 15 others
What the payments were for
- Food & beverage$2,680100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 60 | $825 |
| AbbVie | 53 | $592 |
| Lilly USA, LLC | 20 | $332 |
| Otsuka America Pharmaceutical, Inc. | 5 | $104 |
| Mylan Specialty L.p. | 6 | $100 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $81 |
| Ardelyx, Inc. | 4 | $79 |
| Pfizer | 5 | $73 |
| Amgen | 4 | $68 |
| Exact Sciences | 4 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $52 |
| Boehringer Ingelheim | 3 | $50 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| Xeris Pharmaceuticals, Inc. | 3 | $46 |
| Dexcom, Inc. | 2 | $43 |
| AstraZeneca | 2 | $38 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| GSK | 1 | $18 |
| Bayer | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Viatris Specialty LLC | 1 | $14 |
How this compares
$2,680 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cimzia (2 Pack)Certolizumab Pegol | 11 | $72,824 |
| OzempicSemaglutide | 64 | $59,603 |
| EliquisApixaban | 36 | $40,642 |
| ZenpepLipase/Protease/Amylase | 19 | $39,037 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $29,661 |
| MounjaroTirzepatide | 25 | $27,079 |
| VraylarCariprazine Hcl | 12 | $17,913 |
| LinzessLinaclotide | 31 | $17,010 |
| JardianceEmpagliflozin | 14 | $12,417 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $11,403 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 22 | $10,978 |
| Spiriva HandihalerTiotropium Bromide | 20 | $10,539 |
| Nurtec OdtRimegepant Sulfate | 11 | $10,333 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,208 |
| EntrestoSacubitril/Valsartan | 11 | $8,653 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $825 | $59,60364 claims |
| PfizerEliquis, Nurtec Odt | $73 | $50,97547 claims |
| AbbVieVraylar, Linzess | $592 | $34,92343 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat | $50 | $29,37947 claims |
| Lilly USA, LLCMounjaro | $332 | $27,07925 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $18 | $23,28041 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Nexium | $38 | $17,31342 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.
Other family in Greeneville
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.